(BBC) – The first drug to slow the progression of early stage Alzheimer’s will not be available on the NHS in England because health assessment body NICE says the benefits “are too small to justify the costs”.

Lecanemab has been licensed for use in Great Britain by the medicines regulator, the MHRA, which means it can be prescribed privately. (Read More)